Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 3, 2004, Pages 323-329

  Wong, V W S ^a   Chan, H L Y ^a   Wong, M L ^a   Tam, J S L ^a   Leung, N W Y ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; BIOCHEMISTRY; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; VIRUS MUTANT;

ADULT; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 1342267752     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01845.x     Document Type: Article

References (26)

1. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996; 38(Suppl. 2): S18-23.
2. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 21(1): 77-82.
3. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32(3): 294-8.
4. Liaw YF, Tai DI, Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8(3): 493-6.
5. Liaw YF, Lin DY, Chen TJ, et al. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9(4): 235-41.
6. Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 1999; 58(1): 101-41.
7. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341(17): 1256-63.
8. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339(2): 61-8.
9. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119(1): 172-80.
10. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33(6): 1527-32.
11. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36(6): 687-96.
12. Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32(4 Part 1): 803-6.
13. Schiff ER, Cianciara J, Willems B, et al. Durability of HBeAg responses to lamivudine and interferon in the early post-treatment period in adults with chronic hepatitis B. Hepatology 2000; 32: 337A.
14. Liu CJ, Lai MY, Lee PH, et al. Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience. J Gastroenterol Hepatol 2001; 16(9): 1001-8.
15. Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol 2002; 17(4): 409-14.
16. Honkoop P, de Man RA, Niesters HG, et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32(3): 635-9.
17. Allen MI, Gauthier J, DesLauriers M, et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999; 37(10): 3338-47.
18. Chan HL, Leung NW, Lau TC, et al. Comparison of three different sensitive assays for hepatitis B virus DNA in monitoring of responses to antiviral therapy. J Clin Microbiol 2000; 38(9): 3205-8.
19. Liaw YF, Chien RN, Yeh CT, et al. To continue or not continue lamivudine therapy after emergence of YMDD mutations. Gastroenterology 2002; 122(4): A628.
20. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27(6): 1711-6.
21. Ono-Nita SK, Kato N, Shiratori Y, et al. YMDD motif in hepatitis B virus DNA polymerase influences replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 1999; 29(3): 939-45.
22. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27(2): 628-33.
23. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348(9): 800-7.
24. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348(9): 808-16.
25. Ono-Nita SK, Kato N, Shiratori Y, et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999; 103(12): 1635-40.
26. Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123(6): 1831-8.